stockrow
Saturday 7 November 2026
Export AGIO’s income statement to Excel — free account
Agios Pharmaceuticals, Inc.
AGIO Healthcare Biotechnology
Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024.
- Revenue
- +330.0%
- EPS
- +38.8%
- Free cash flow
- +32.6%
Quarter to September 2026, against a year earlier
29.41
1.14
+4.03%
Follow AGIO
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | — | — | — | 5 | 3 | 5 | 2 | 4 |
P/E ratio |
0.00 | 2.79 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
29.21 | 51.15 | 47.37 | 105.92 | — | 14.71 | 24.30 | 28.05 | 64.81 | 24.20 |
Altman Z-Score |
8.12 | 8.85 | 4.30 | 5.88 | — | 0.63 | 4.15 | 6.94 | 3.90 | 2.62 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 59.03 |
Altman Z″-Score (non-manufacturers) |
12.52 | 14.71 | 6.45 | 9.11 | — | (4.60) | (1.43) | 1.17 | (2.35) | 1.72 |
P/Operating CF |
(16.40) | (14.02) | (17.53) | (22.80) | — | (60.52) | (30.60) | (35.69) | (37.44) | (33.01) |
Beneish M-Score |
(1.72) | 2.39 | (2.43) | — | — | — | (1.57) | (1.10) | (2.22) | (4.83) |
P/B ratio |
1.32 | 1.21 | 1.57 | 1.37 | — | 7.48 | 4.47 | 3.85 | 7.42 | 4.72 |
Price to Tangible BV |
1.32 | 1.21 | 1.57 | 1.37 | — | 7.48 | 4.47 | 3.85 | 7.42 | 4.72 |
EV/Sales |
13.40 | 26.67 | 18.41 | 50.95 | — | 11.90 | 19.51 | 21.85 | 54.95 | 16.45 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.94) | (2.50) | (1.67) | (2.34) | — | (8.31) | (6.21) | (6.77) | (8.29) | 29.82 |
EV/FCF |
(1.92) | (2.49) | (1.67) | (2.31) | — | (7.93) | (6.01) | (6.62) | (8.15) | 40.13 |
Quick Ratio |
10.52 | 11.06 | 11.47 | 12.54 | 17.12 | 6.34 | 6.25 | 6.37 | 4.50 | 6.22 |
Current Ratio |
11.46 | 11.90 | 12.27 | 13.30 | 17.79 | 6.74 | 6.59 | 6.56 | 4.69 | 6.33 |
Net Debt/EBITDA |
1.80 | 2.06 | 1.99 | 2.05 | 2.82 | 1.77 | 1.81 | 1.63 | 1.35 | 2.78 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.02% | 0.04% | 0.08% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.03 | 0.02 | 0.01 | 0.00 | 0.23 | 0.13 | 0.13 | 0.07 | 0.13 |
Operating CF/Net income |
0.90 | (0.58) | 0.84 | 1.34 | (0.25) | 0.89 | 0.90 | 0.88 | 0.91 | (0.19) |
Capex/Depreciation |
2.14 | 0.19 | 0.21 | (0.53) | (0.35) | (1.10) | (2.46) | (2.09) | (0.72) | (1.53) |
| (30.20%) | 57.29% | (36.83%) | (19.37%) | 189.74% | (62.95%) | (61.97%) | (65.10%) | (85.73%) | (56.41%) | |
| (27.89%) | 51.82% | (32.36%) | (17.32%) | 140.11% | (37.55%) | (47.05%) | (46.99%) | (51.02%) | (38.20%) | |
ROIC |
(87.12%) | (41.11%) | (717.72%) | (76.54%) | (86.88%) | 0.00% | (258.99%) | (221.60%) | 0.00% | 0.00% |
Return on Tangible Assets |
(47.41%) | 75.18% | (45.07%) | (29.23%) | 155.30% | (57.12%) | (74.77%) | (63.54%) | (83.97%) | (39.95%) |
Average Days of Receivables |
71.46 | 41.09 | 38.24 | 56.54 | 0.00 | 45.62 | 47.42 | 40.38 | 31.14 | 43.42 |
Research and Development Expense of Revenue |
628.44% | 825.49% | 1,101.76% | 1,965.66% | 0.00% | 108.67% | 181.71% | 361.62% | 680.48% | 315.00% |
Selling, General and Administrative Expense of Revenue |
333.68% | 429.57% | 447.02% | 854.45% | 0.00% | 56.65% | 86.51% | 120.93% | 165.36% | 72.56% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
97.27% | 117.40% | 166.89% | 346.18% | 0.00% | 30.32% | 49.23% | 77.72% | 111.16% | 60.22% |
Graham Net Nets |
0.53 | 0.45 | 0.56 | 0.46 | — | 0.06 | 0.13 | 0.17 | 0.07 | 0.18 |
Graham Number |
0.00 | 84.83 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(26.12%) | 35.88% | (27.77%) | (15.40%) | — | (10.94%) | (14.39%) | (13.08%) | (11.27%) | (11.68%) |
Free Cash Flow Yield |
(23.91%) | (20.97%) | (23.28%) | (20.78%) | — | (10.20%) | (13.36%) | (11.76%) | (10.40%) | 1.69% |
Revenue per Share |
0.93 | 0.64 | 0.48 | 0.26 | 0.00 | 2.95 | 1.97 | 1.64 | 0.92 | 1.79 |
Operating CF per Share |
(6.43) | (6.86) | (5.32) | (5.65) | (6.74) | (4.21) | (6.18) | (5.30) | (6.12) | 0.99 |
Capex per Share |
(0.07) | (0.03) | 0.01 | (0.07) | (0.09) | (0.20) | (0.20) | (0.12) | (0.10) | (0.25) |
Free Cash Flow per Share |
(6.51) | (6.89) | (5.31) | (5.72) | (6.83) | (4.42) | (6.38) | (5.42) | (6.22) | 0.73 |
Cash per Share |
14.74 | 15.73 | 13.96 | 14.29 | 16.87 | 8.30 | 9.42 | 10.19 | 9.10 | 13.84 |
Shareholders Equity per Share |
20.58 | 27.13 | 14.57 | 20.09 | 21.37 | 5.79 | 10.68 | 11.97 | 8.06 | 9.16 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
20.58 | 27.13 | 14.57 | 20.09 | 21.37 | 5.79 | 10.68 | 11.97 | 8.06 | 9.16 |
Free Cash Flow |
(377.29) | (391.49) | (295.74) | (313.39) | (413.06) | (304.86) | (382.65) | (311.41) | (289.86) | 28.65 |
Working Capital |
859.85 | 884.44 | 765.88 | 770.14 | 1,004.41 | 542.28 | 518.82 | 520.28 | 350.32 | 471.46 |
Capital Expenditures |
(4.32) | (1.64) | 0.33 | (3.92) | (5.74) | (14.11) | (12.03) | (6.99) | (4.63) | (9.91) |
Net Current Asset Value |
837.94 | 843.36 | 707.74 | 694.87 | 918.47 | 183.23 | 361.49 | 442.86 | 206.37 | 299.39 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.08 | 0.05 | (0.01) | 0.28 | 0.00 | 0.07 | 0.10 | 0.07 | 0.11 | 0.14 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.19) | (0.76) | 0.10 | 0.32 | 0.56 | 0.42 | 0.16 | 0.14 | 0.26 | 0.26 |
Cash ROIC |
(18.43%) | (16.08%) | (18.62%) | (16.64%) | (17.86%) | (31.34%) | (31.73%) | (24.47%) | (36.26%) | 3.18% |
Accounts Receivable Turnover |
7.36 | 10.55 | 10.70 | 4.33 | 0.00 | 9.98 | 9.15 | 13.38 | 7.18 | 7.02 |
Accounts Payable Turnover |
0.36 | 0.32 | 0.20 | 0.10 | 1.09 | 0.95 | 0.90 | 0.07 | 0.00 | 0.00 |
Inventory Turnover |
0.21 | 0.18 | 0.21 | 0.15 | 0.00 | 1.70 | 4.37 | 0.35 | — | — |
Average Days of Payables |
1,055.88 | 1,458.51 | 1,239.05 | 3,987.58 | 324.63 | 344.62 | 445.59 | 4,671.58 | 0.00 | 0.00 |
Days of Inventory on Hand |
1,893.74 | 2,420.13 | 2,416.78 | 1,819.00 | 0.00 | 285.79 | 149.19 | 227.05 | — | — |
Average Receivables |
7.34 | 3.46 | 2.51 | 3.29 | 14.89 | 20.36 | 12.88 | 7.06 | 5.99 | 9.96 |
Average Payables |
17.50 | 13.21 | 14.20 | 17.66 | 17.21 | 19.81 | 19.89 | 20.32 | 19.94 | 15.93 |
Average Inventory |
30.27 | 23.35 | 13.78 | 11.60 | — | 11.01 | 4.10 | 4.00 | — | — |
Average Assets |
1,480.21 | 1,300.16 | 1,087.92 | 1,338.23 | 1,145.34 | 871.85 | 874.60 | 736.43 | 616.75 | 519.58 |
Average Common Equity |
1,367.04 | 1,175.99 | 955.92 | 1,196.39 | 845.74 | 520.01 | 664.03 | 531.52 | 367.05 | 351.85 |
Columns are period end dates · fundamentals updated 5 Nov 2026